ArticleBlood research2019

What is the most appropriate regimen for untreated Waldenström macroglobulinemia? - An updated analysis of rituximab and half-dose CHOP therapy and cost effectiveness.

Naohiro Sekiguchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.